NASDAQ:PDEX Pro-Dex (PDEX) Stock Price, News & Analysis $71.77 -1.25 (-1.71%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$71.77 0.00 (0.00%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Pro-Dex Stock (NASDAQ:PDEX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pro-Dex alerts:Sign Up Key Stats Today's Range$70.85▼$74.2050-Day Range$53.43▼$73.4152-Week Range$23.47▼$77.00Volume59,961 shsAverage Volume75,909 shsMarket Capitalization$229.66 millionP/E Ratio17.38Dividend YieldN/APrice Target$74.00Consensus RatingBuy Company Overview Pro-Dex, Inc. is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands. Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers. Based in Irvine, California, Pro-Dex serves customers in the United States and international markets. Its products are used in areas such as orthopedic, spinal, dental and other specialized surgical applications. The company’s business is focused on combining medical-device engineering and contract manufacturing capabilities to produce instruments designed for specific clinical and OEM requirements.AI Generated. May Contain Errors. Read More Pro-Dex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScorePDEX MarketRank™: Pro-Dex scored higher than 59% of companies evaluated by MarketBeat, and ranked 391st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingBuy Consensus RatingPro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Pro-Dex is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoveragePro-Dex has only been the subject of 3 research reports in the past 90 days.Read more about Pro-Dex's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.74% Earnings GrowthEarnings for Pro-Dex are expected to grow by 8.74% in the coming year, from $3.09 to $3.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro-Dex is 17.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.64.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro-Dex is 17.38, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.Price to Book Value per Share RatioPro-Dex has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pro-Dex's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.11% of the float of Pro-Dex has been sold short.Short Interest Ratio / Days to CoverPro-Dex has a short interest ratio ("days to cover") of 2.29, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pro-Dex has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPro-Dex does not currently pay a dividend.Dividend GrowthPro-Dex does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.60 News SentimentPro-Dex has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pro-Dex this week, compared to 1 article on an average week.Search Interest5 people have searched for PDEX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pro-Dex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,351,657.00 in company stock.Percentage Held by Insiders45.90% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.28% of the stock of Pro-Dex is held by institutions.Read more about Pro-Dex's insider trading history. Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PDEX Stock News HeadlinesContrasting Precision Optics (NASDAQ:POCI) & Pro-Dex (NASDAQ:PDEX)September 25 at 2:15 AM | americanbankingnews.comAscendiant Capital Markets Forecasts Pro-Dex Q4 EarningsSeptember 19, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 27 at 1:00 AM | Stansberry Research (Ad)Pro-Dex Q1 EPS Estimate Lifted by Ascendiant Capital MarketsSeptember 18, 2026 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) CEO Sells 765 Shares of StockSeptember 15, 2026 | insidertrades.comPro-Dex (NASDAQ:PDEX) CFO Sells 2,300 SharesSeptember 11, 2026 | insidertrades.com5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & MoreSeptember 4, 2026 | rttnews.comPro-Dex Jumps On Higher Q4 Earnings And Revenue GrowthSeptember 4, 2026 | rttnews.comSee More Headlines PDEX Stock Analysis - Frequently Asked Questions How have PDEX shares performed this year? Pro-Dex's stock was trading at $38.48 on January 1st, 2026. Since then, PDEX shares have increased by 86.5% and is now trading at $71.77. How were Pro-Dex's earnings last quarter? Pro-Dex, Inc. (NASDAQ:PDEX) released its earnings results on Thursday, September, 3rd. The medical instruments supplier reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.20. The medical instruments supplier had revenue of $20.41 million for the quarter, compared to the consensus estimate of $19.20 million. Pro-Dex had a trailing twelve-month return on equity of 25.13% and a net margin of 17.62%. Who are Pro-Dex's major shareholders? Top institutional shareholders of Pro-Dex include Bank of New York Mellon Corp (0.36%), Navellier & Associates Inc. (0.17%) and California State Teachers Retirement System. Insiders that own company stock include Kirk Richard Lee Van Jr, Alisha Charlton and Angelita Rebamontan Domingo. View institutional ownership trends. How do I buy shares of Pro-Dex? Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL). Company Calendar Last Earnings9/03/2026Today9/27/2026Next Earnings (Estimated)10/29/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PDEX's financial health is in the Green zone, according to TradeSmith. PDEX has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:PDEX CIK788920 Webwww.pro-dex.com Phone(949) 769-3200Fax949-769-3281Employees206Year Founded1975Price Target and Rating Average Price Target for Pro-Dex$74.00 High Price Target$74.00 Low Price Target$74.00 Potential Upside/Downside+3.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$4.13 Trailing P/E Ratio17.38 Forward P/E Ratio23.23 P/E GrowthN/ANet Income$13.66 million Net Margins17.62% Pretax Margin23.23% Return on Equity25.13% Return on Assets16.02% Debt Debt-to-Equity Ratio0.28 Current Ratio4.10 Quick Ratio2.45 Sales & Book Value Annual Sales$77.55 million Price / Sales2.96 Cash Flow$3.90 per share Price / Cash Flow18.39 Book Value$14.92 per share Price / Book4.81Miscellaneous Outstanding Shares3,200,000Free Float1,733,000Market Cap$229.66 million OptionableNot Optionable Beta0.06 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PDEX) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro-Dex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
